Newsroom | 21932 results

BASEL, Switzerland--(BUSINESS WIRE)--Malaria gehört zu den tödlichsten Krankheiten der Welt und breitet sich trotz jahrzehntelanger Bemühungen und einiger Erfolge auf dem Weg zur Ausrottung weiter aus. Nach Angaben der Weltgesundheitsorganisation (WHO) infizierten sich weltweit 263 Millionen Menschen mit Malaria, und allein im Jahr 2023 starben beinahe 600 000 Menschen an der Krankheit – 75 % davon Kinder unter fünf Jahren. 94% der Erkrankten leben in Afrika, wo Malaria ganze Gemeinden zerstöre...

巴塞尔--(BUSINESS WIRE)--(美国商业资讯)-- 疟疾是全球致命性最强的疾病之一。尽管人类数十年的防控努力取得了阶段性成果，其威胁却仍在加剧。世界卫生组织（WHO）数据显示，2023年全球疟疾感染人数达2.63亿，导致近60万人死亡，其中75%为5岁以下儿童。94%的感染病例集中在非洲——在当地，疟疾不仅破坏社区发展，更重创经济。 疟疾通过携带疟原虫的蚊虫传播，而这类蚊虫具有极强的进化适应能力，其蔓延态势不仅反映出杀虫剂抗性广泛存在的现实情况，也凸显了新防控方案研发所面临的严峻挑战。在此背景下，蚊虫的有效防控仍是阻断疾病传播的核心策略。 全球农业创新领军企业先正达今日宣布，新一代杀虫剂Sovrenta®正式获得世界卫生组织预认证，为其在疟疾肆虐国家的落地应用铺平道路。数十年来，先正达一直站在抗击疟疾的前线，通过自主研发，并与撒哈拉以南非洲地区核心伙伴深度合作，积极探索创新解决方案。旗下Actellic®等产品已帮助30余个国家成功预防超1亿疟疾病例。 Sovrenta®通过靶向蚊虫神经系统，阻断其肌肉放松信号传导，从而使其麻痹并最终死亡。长效防控，单季单次施药即可见效，...

BÂLE, Suisse--(BUSINESS WIRE)--Le paludisme est l'une des maladies les plus mortelles au monde, et il devient de plus en plus répandu - malgré des décennies d'efforts et quelques succès sur la voie de son éradication. Selon l'Organisation Mondiale de la Santé (OMS), le paludisme a infecté 263 millions de personnes et tué près de 600 000 personnes en 2023 - dont 75 % étaient des enfants de moins de 5 ans. Parmi les personnes touchées, 94 % se trouvent en Afrique - où le paludisme écrase les comm...

BASEL, Switzerland--(BUSINESS WIRE)--Malaria is one of the world’s most deadly diseases, and it is becoming more pervasive – despite decades of effort and some successes on the path to eradicating it. According to the World Health Organization (WHO), malaria infected 263 million people and killed nearly 600,000 people in 2023 – 75% of whom were children under the age of 5. Of those afflicted, 94% are in Africa – where malaria crushes communities and can cripple economies. Spread by parasites in...

BLACKSBURG, Va.--(BUSINESS WIRE)--The NIMML Institute, (“NIMML”), a 501 (c)(3) nonprofit research institute dedicated to the discovery of novel precision medicines for infectious and autoimmune diseases, today announced publication of four new case studies in the Annual Review of Biomedical Data Science. Together, they demonstrate how the A.I.-powered TITAN-X Precision Medicine Platform (“TITAN-X”) has been leveraged to identify therapeutic targets and fueled the development of multiple therape...

MANHASSET, N.Y.--(BUSINESS WIRE)--Researchers at Northwell Health’s Feinstein Institutes for Medical Research found that obinutuzumab, a therapeutic antibody that depletes B cells and is approved for the treatment of B cell malignancies, benefitted patients with lupus nephritis, a severe complication of lupus that compromises kidney function. The study, which was led by Richard A. Furie, MD, professor in the Feinstein Institutes’ Institute of Molecular Medicine and The Marilyn and Barry Rubenst...

MEXICO CITY & MIAMI & SÃO PAULO--(BUSINESS WIRE)--The AIDS Healthcare Foundation (AHF) and the AHF Global Public Health Institute acknowledge the conclusion of three years of negotiations on the global pandemic agreement text by congratulating the negotiators—particularly representatives of the Equity and Africa Groups—and recognizing the contributions of key stakeholders, including civil society, who championed equitable access to public health goods. “Even before the COVID-19 pandemic, we beg...

PHILADELPHIA--(BUSINESS WIRE)--AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices...

PHILADELPHIA--(BUSINESS WIRE)--GSK’s 5-in-1 meningococcal vaccine PENMENVY receives positive recommendation from US Advisory Committee on Immunization Practices...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug...